治療によって誘発されるAPOBEC3Aは,がん細胞の進化を誘発する
Hideko Isozaki1,2, Ramin Sakhtemani3,4, Ammal Abbasi3
1Massachusetts General Hospital Cancer Center, Boston, MA, USA. hisozaki@mgh.harvard.edu.
Nature
|July 5, 2023
まとめ
標的型肺がん治療はAPOBEC3A (A3A) を誘導し,持続性のあるがん細胞に変異を引き起こす可能性があります. A3Aを抑制すると,薬剤耐性が遅れる可能性があり,新しい治療戦略が提供されます.
科学分野:
- 腫瘍学
- 遺伝学
- 分子生物学
背景:
- 標的型抗がん療法に対する薬剤耐性獲得は大きな臨床的課題です.
- 治療中の腫瘍の進化のメカニズム,特に薬剤耐性については,完全に理解されていません.
- ゲノム研究により,アポリプロテインBメッセンジャーRNA編集型触媒型ポリペプチド型 (APOBEC) サイチジンデアミナーゼが腫瘍の進化における役割を示唆している.
研究 の 目的:
- 肺がんの標的治療中に薬剤耐性の発達におけるAPOBECサイチジンデアミナーゼ,特にAPOBEC3A (A3A) の役割を調査する.
- 標的治療がA3Aを誘導し,これが腫瘍の進化と抵抗に寄与するかどうかを判断する.
主な方法:
- 肺がん細胞と患者の腫瘍の分析
- 標的治療によるA3A誘導の評価
- 薬剤耐性持続細胞におけるAPOBEC媒介型変異とゲノム不安定性の評価
- 耐性への影響を評価するためにA3Aの遺伝子削除
- 患者の腫瘍におけるAPOBEC変異シグネチャーの分析
主要な成果:
- 一般的な肺がんの標的治療は,薬剤耐性の持続細胞にAPOBEC3A (A3A) を誘導する.
- 治療によって誘発されるA3Aは,持続的な変異とゲノム不安定性の増加につながります.
- A3Aの削除はAPOBECの変異と構造的変異を減少させ,薬剤耐性を遅らせました.
- APOBECの変異シグネチャーは,最初の反応後に耐性を発症した肺がん患者で発見されました.
結論:
- 標的治療によるA3A誘導は,薬剤耐性の持続細胞の進化を誘導する.
- A3Aは肺がんにおける薬剤耐性の獲得に重要な役割を果たします.
- A3Aの活性または発現を抑制することは,肺がんの標的治療に対する抵抗を予防または遅らせるための治療戦略である.
さらに関連する動画
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
14.4K
06:29Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland
Published on: June 7, 2019
12.8K
関連する概念動画
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancers Originate from Somatic Mutations in a Single Cell
12.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.1K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
